Second Cancer After Additive Chemotherapy in Patients With Colon Cancer
Teufel A, Li M, Gerken M, Ebert MP, Schlitt HJ, Evert M, Herr W, Klinkhammer-Schalke M (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 21
Pages Range: 354-361
Journal Issue: 4
DOI: 10.1016/j.clcc.2022.07.002
Abstract
Background: Additive chemotherapeutic treatment of UICC-stage -III / IV colon cancer with fluorouracil, leucovorin and oxaliplatin is widely accepted as current standard of treatment after R0-resection. However, as patients. survival is increasing, long-term side effects of chemotherapeutic agents such as second cancer development are becoming increasingly important. Patients: We therefore investigated a total of 2 856 Patients with UICC-stage III / IV colon cancer, 223 of whom (7.8%) had developed a subsequent second cancer. Results: Median follow-up was 73.2 months (range 209.9 months, 95%-CI 69.8-76.9). Most frequent second cancers were prostate cancer (18.4%), colon cancer (16.1%), breast cancers (8.1%), lung cancer (8.1%), rectal cancer (4.9%) and uterine cancer (4.9%). However, in comparison to non-treated patients this did not represent a significantly increased risk for subsequent second cancer in patients after treatment with additive chemotherapy. Of interest, our data suggest a significantly decreased second cancer rate in patients treated with FOLFOX compared to FUFOL for additive treatment. Conclusions: Second cancer development was not increased after additive chemotherapy for colon cancer, which is a novel aspect in the ongoing discussions on reduction of adjuvant treatment to 3 months or treatment of lymph node negative patients. Novelty and Impact Statement To our knowledge, this is the first population-based study analyzing second cancer development after additive chemotherapy in patients with UICC III-IV colon cancer. The results have an important impact on the surveillance and long-term follow-up of cancer patients.
Involved external institutions
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universität Regensburg
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Germany (DE)
Universität Regensburg
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
How to cite
APA:
Teufel, A., Li, M., Gerken, M., Ebert, M.P., Schlitt, H.J., Evert, M.,... Klinkhammer-Schalke, M. (2022). Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. Clinical Colorectal Cancer, 21(4), 354-361. https://doi.org/10.1016/j.clcc.2022.07.002
MLA:
Teufel, Andreas, et al. "Second Cancer After Additive Chemotherapy in Patients With Colon Cancer." Clinical Colorectal Cancer 21.4 (2022): 354-361.
BibTeX: Download